Draper Fisher Jurvetson closes fund with $325M

Draper Fisher Jurvetson has closed its 11th venture fund with $325 million. The firm has placed a few bets in the life sciences field, including its support for NanoString's ($NSTG) diagnostics work. While Tim Draper and John Fisher remain on the management committee, both have other interests now that will preclude them working as investment partners. Draper will be spending his time at Draper University, where he'll be focusing on restoring the country's seed financing ecosystem. Report

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.